Market closedNon-fractional

Beam Therapeutics/BEAM

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Ticker

BEAM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

346
Website
beamtx.com

BEAM Metrics

BasicAdvanced
$1.8B
Market cap
-
P/E ratio
-$1.69
EPS
1.88
Beta
-
Dividend rate
$1.8B
1.88
5.991
5.846
17.071
18.404
-8.44%
-16.09%
4.97
1.95
1.95
-10.6
370.57%
-62.01%
2,368.29%
-36.94%

What the Analysts think about BEAM

Analyst Ratings

Majority rating from 15 analysts.
Buy

BEAM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,332.43% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.4M
-97.66%
Net income
-$99M
-169.10%
Profit margin
-1,332.43%
-3,051.77%

BEAM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.63%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.08
-$1.22
$1.73
-$1.21
-
Expected
-$1.42
-$1.36
-$1.01
-$1.42
-$1.14
Surprise
-24.19%
-10.40%
-271.08%
-14.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Beam Therapeutics stock?

Beam Therapeutics (BEAM) has a market cap of $1.8B as of July 05, 2024.

What is the P/E ratio for Beam Therapeutics stock?

The price to earnings (P/E) ratio for Beam Therapeutics (BEAM) stock is 0 as of July 05, 2024.

Does Beam Therapeutics stock pay dividends?

No, Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Beam Therapeutics dividend payment date?

Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders.

What is the beta indicator for Beam Therapeutics?

Beam Therapeutics (BEAM) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Beam Therapeutics stock

Buy or sell Beam Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing